INTERNATIONAL PATENT: PACYLEX PHARMACEUTICALS INC. FILES APPLICATION FOR "MYRISTOYLATION INHIBITOR SENSITIVITY SIGNATURE MISS-54, IDENTIFIES NEW CANCER INDICATIONS FOR NMT INHIBITOR PCLX-001"

GENEVA, Oct. 12 -- PACYLEX PHARMACEUTICALS INC. (400 3rd Avenue SW, Suite 3700Calgary, Alberta T2P 4H2) filed a patent application (PCT/CA2025/050470) for "MYRISTOYLATION INHIBITOR SENSITIVITY SIGNATURE MISS-54, IDENTIFIES NEW CANCER INDICATIONS FOR NMT INHIBITOR PCLX-001" on Apr 02, 2025. With publication no. WO/2025/208214, the details related to the patent application was published on Oct 09, 2025.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Inventor(s): BEAUCHAMP, Erwan (7711 79 AvenueEdmonton, Alberta T6C 0P5), GAMMA, Jay Morgan (3006 108 Street NWEdmonton, Alberta T6J 3S6), BERTHIAUME, Luc G. (10061 ...